233 related articles for article (PubMed ID: 29064353)
1. Dual ET
Nadeau V; Potus F; Boucherat O; Paradis R; Tremblay E; Iglarz M; Paulin R; Bonnet S; Provencher S
Pulm Circ; 2018; 8(1):2045893217741429. PubMed ID: 29064353
[TBL] [Abstract][Full Text] [Related]
2. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
3. Selective improvement of pulmonary arterial hypertension with a dual ET
Renshall L; Arnold N; West L; Braithwaite A; Pickworth J; Walker R; Alfaidi M; Chamberlain J; Casbolt H; Thompson AAR; Holt C; Iglarz M; Francis S; Lawrie A
Pulm Circ; 2018; 8(1):2045893217752328. PubMed ID: 29261014
[TBL] [Abstract][Full Text] [Related]
4. Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.
Drozd K; Ahmadi A; Deng Y; Jiang B; Petryk J; Thorn S; Stewart D; Beanlands R; deKemp RA; DaSilva JN; Mielniczuk LM
J Nucl Cardiol; 2017 Dec; 24(6):1979-1989. PubMed ID: 27688036
[TBL] [Abstract][Full Text] [Related]
5. The endothelin system in pulmonary arterial hypertension.
Galié N; Manes A; Branzi A
Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
[TBL] [Abstract][Full Text] [Related]
6. Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells.
Sakai S; Maruyama H; Kimura T; Tajiri K; Honda J; Homma S; Aonuma K; Miyauchi T
Life Sci; 2016 Aug; 159():116-120. PubMed ID: 27021787
[TBL] [Abstract][Full Text] [Related]
7. Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension.
Yu J; Taylor L; Wilson J; Comhair S; Erzurum S; Polgar P
J Cell Physiol; 2013 Feb; 228(2):322-9. PubMed ID: 22688668
[TBL] [Abstract][Full Text] [Related]
8. Macitentan: An important addition to the treatment of pulmonary arterial hypertension.
Khadka A; Singh Brashier DB; Tejus A; Sharma AK
J Pharmacol Pharmacother; 2015; 6(1):53-7. PubMed ID: 25709357
[TBL] [Abstract][Full Text] [Related]
9. β3 adrenergic agonism: A novel pathway which improves right ventricular-pulmonary arterial hemodynamics in pulmonary arterial hypertension.
Karimi Galougahi K; Zhang Y; Kienzle V; Liu CC; Quek LE; Patel S; Lau E; Cordina RL; Figtree GA; Celermajer DS
Physiol Rep; 2023 Jan; 11(1):e15549. PubMed ID: 36597221
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
12. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
13. Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis.
Shinohara T; Sawada H; Otsuki S; Yodoya N; Kato T; Ohashi H; Zhang E; Saitoh S; Shimpo H; Maruyama K; Komada Y; Mitani Y
Am J Physiol Lung Cell Mol Physiol; 2015 Mar; 308(6):L523-38. PubMed ID: 25539851
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Ohtsuki T; Al-Mamun ME; Siddique MAH; Yaoita N; Sunamura S; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
Circ Res; 2019 Oct; 125(10):884-906. PubMed ID: 31556812
[TBL] [Abstract][Full Text] [Related]
15. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
[TBL] [Abstract][Full Text] [Related]
17. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
18. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
Morales-Cano D; Izquierdo-García JL; Barreira B; Esquivel-Ruiz S; Callejo M; Pandolfi R; Villa-Valverde P; Rodríguez I; Cogolludo A; Ruiz-Cabello J; Perez-Vizcaino F; Moreno L
Front Pharmacol; 2023; 14():1021535. PubMed ID: 37063275
[No Abstract] [Full Text] [Related]
19. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
20. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
